

Funding Applications going to the February 2012 PTAC Meeting

Details of Funding Applications received are published on PHARMAC's website, in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008.

Chemical (Trade) names	Indication	Applicant	Date Received
Dutasteride (Avodart)	Benign Prostatic Hyperplasia	GlaxoSmithKline	22/11/2011
Certolizumab (Cimzia)	Rheumatoid Arthritis	UCB	22/11/2011
Vemurafenib (Zelboraf)	Stage IIIC/IV Melanoma with BRAF V600 Mutation	Roche	22/11/2011
Indacaterol (ONBREZ inhaler)	Chronic Obstructive Pulmonary Disease	Novartis	22/11/2011
Fingolimod (Gilenya)	Multiple Sclerosis	Novartis	22/11/2011
Eculizumab (Solaris)	Paroxysmal Nocturnal Haemaglobinuria	Alexion	22/11/2011
Eltrombopag (Revolade)	Idiopathic Thrombocytopenic Purpura (ITP)	GlaxoSmithKline	22/11/2011